Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENYTOIN vs AZMIRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.
Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.
Generalized tonic-clonic seizures (grand mal epilepsy),Complex partial seizures (psychomotor/temporal lobe seizures),Prevention and treatment of seizures occurring during or following neurosurgery,Status epilepticus (intravenous formulation)
Treatment of Ductal Carcinoma In Situ (DCIS) following breast surgery and radiation,Breast cancer risk reduction in premenopausal women at high risk,Off-label: Anovulatory infertility, Osteoporosis prevention in postmenopausal women
Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.
Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.
Average terminal half-life 22 hours (range 7–42 hours) in adults; dose-dependent due to saturation of metabolism at therapeutic concentrations (10–20 mg/L). Half-life increases with higher doses.
Terminal elimination half-life: 4.5 hours (range 3–6 h); supports twice-daily dosing.
Phenytoin is extensively metabolized in the liver primarily by the cytochrome P450 enzyme CYP2C9, with minor contributions from CYP2C19. The major metabolite is the glucuronide conjugate of 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH). Phenytoin exhibits dose-dependent, saturable (Michaelis-Menten) pharmacokinetics.
Primarily metabolized via hepatic glucuronidation by UGT1A4 and UGT1A8; minor metabolism by CYP3A4; excreted mainly in feces.
Primarily hepatic metabolism (>95%); less than 5% excreted unchanged in urine. Renal excretion of metabolites (glucuronides) accounts for ~80% of elimination; biliary/fecal excretion of metabolites ~20%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
90–95% bound, primarily to albumin; binding is saturable and decreases in hypoalbuminemia, uremia, or with other highly bound drugs.
98% bound to albumin and alpha-1-acid glycoprotein.
0.6–0.8 L/kg; indicates extensive tissue distribution; crosses blood-brain barrier; Vd increases in neonates and decreases in renal failure.
0.8 L/kg; indicates moderate tissue distribution.
Oral: 90–100% (phenytoin sodium extended-release); IM: low and erratic (not recommended) due to precipitation and slow absorption.
Oral: 60% (first-pass metabolism reduces to ~60% absolute).
No specific GFR-based adjustment required; use with caution in severe renal impairment (GFR < 10 m L/min) due to protein binding changes.
Cr Cl ≥50 m L/min: no adjustment; Cr Cl 30-49 m L/min: 400 mg every 8 hours; Cr Cl 15-29 m L/min: 300 mg every 12 hours; Cr Cl <15 m L/min or hemodialysis: 300 mg every 24 hours.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 25-50%; Child-Pugh C: Reduce dose by 50-75%.
Child-Pugh A: no adjustment; Child-Pugh B: 400 mg every 8 hours; Child-Pugh C: 300 mg every 12 hours.
Loading dose: 15-20 mg/kg IV/PO; Maintenance: 5-10 mg/kg/day PO in 2-3 divided doses.
For children ≥2 years: 10 mg/kg/dose IV every 8 hours, maximum 600 mg/dose.
Start at low end of dosing range (e.g., 3 mg/kg/day); monitor for toxicity; consider reduced protein binding and slower metabolism.
No specific dose adjustment based solely on age; dose based on renal function as per renal adjustment guidelines.
Intravenous administration of phenytoin is associated with serious cardiovascular adverse reactions including severe hypotension and cardiac arrhythmias (e.g., bradycardia, heart block, ventricular fibrillation). These reactions can occur more frequently in patients with advanced age, known cardiac disease, or those receiving other medications that affect the cardiovascular system. Continuous monitoring of ECG and vital signs is required during IV administration, and the rate of infusion should not exceed 50 mg/min in adults.
Increased risk of thromboembolic events including deep vein thrombosis and pulmonary embolism; increased risk of endometrial cancer, uterine sarcoma, and stroke.
Cardiovascular risk during IV administration (see black box warning),Hypersensitivity reactions: Angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS),Hepatic injury: Acute hepatotoxicity, including elevated liver enzymes and hepatitis,Hematologic effects: Agranulocytosis, thrombocytopenia, leukopenia, pancytopenia,Central nervous system effects: Nystagmus, ataxia, slurred speech, mental confusion, dizziness, drowsiness,Hyperglycemia: May elevate blood glucose levels,Osteomalacia and hypocalcemia due to altered vitamin D metabolism,Teratogenicity: Fetal hydantoin syndrome (craniofacial abnormalities, growth deficiency, intellectual disability),Birth defects: Increased risk of cardiovascular malformations and neural tube defects,Carcinogenicity: Long-term use associated with increased risk of malignancies (lymphoma, hepatocellular carcinoma)
Risk of thromboembolic events; endometrial hyperplasia and malignancy; hepatic steatosis and elevated liver enzymes; cataracts; hypertriglyceridemia; use in pregnancy category N (should not be used during pregnancy).
Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation,Sinus bradycardia, sinoatrial block, second- or third-degree AV block, Adams-Stokes syndrome,Concurrent use with delavirdine (due to decreased delavirdine concentrations),History of prior acute hepatotoxicity attributable to phenytoin,Porphyria (may precipitate acute attacks)
History of venous thromboembolism; pregnancy; women with a history of stroke or transient ischemic attack; hypersensitivity to azmiro or its components.
Enteral tube feedings can decrease phenytoin absorption; hold feeds 1-2 hours before and after administration. High-fat meals may increase absorption consistency. Folic acid supplementation may lower phenytoin levels. Calcium supplements and antacids can impair absorption; separate by 2-3 hours.
No significant food interactions. Avoid grapefruit juice as it may increase systemic budesonide exposure. Maintain adequate calcium and vitamin D intake due to potential bone density loss with long-term use.
Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during first trimester (organogenesis). Second and third trimester exposure may cause impaired fetal growth, microcephaly, and neurodevelopmental delay. Risk of major malformations is dose-dependent and increases with polytherapy.
No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).
Phenytoin is excreted into breast milk with estimated infant dose of 2-10% of maternal weight-adjusted dose; M/P ratio approximately 0.18-0.45. Generally considered compatible with breastfeeding; monitor infant for drowsiness, poor feeding, and rash. Avoid if maternal dose >400 mg/day or signs of infant toxicity.
No data on excretion in human milk; unknown M/P ratio. Risk to infant cannot be excluded; consider developmental benefits of breastfeeding versus theoretical risk.
Pregnancy decreases phenytoin concentrations due to increased clearance (hepatic induction, increased Vd, decreased albumin). Dose adjustments are frequently required: increase total daily dose by 30-50% on average, guided by free phenytoin concentrations (target 1-2 mcg/m L). Monitor serum levels every 2-4 weeks, especially in third trimester. Postpartum, dose should be reduced to prepregnancy levels over 1-2 weeks to avoid toxicity.
No specific dose adjustments studied; pharmacokinetics in pregnancy unknown. Use lowest effective dose and monitor therapeutic response.
Phenytoin exhibits zero-order kinetics at therapeutic levels; small dose increases can cause toxicity. Monitor free phenytoin levels in hypoalbuminemia or uremia. Fosphenytoin is a prodrug used for IV loading with fewer infusion-site reactions. Caution in CYP2C9 poor metabolizers; consider genetic testing. May cause folate deficiency, peripheral neuropathy, and osteomalacia with long-term use. Co-administration with valproate displaces phenytoin from protein binding, increasing free fraction.
AZMIRO (budesonide/albuterol) is a fixed-dose combination inhaler for asthma. Due to its LABA component, it should not be used for acute bronchospasm. Titrate to the lowest effective dose. Rinse mouth after inhalation to reduce oral candidiasis and dysphonia. Monitor for increased heart rate and blood pressure, especially with excessive use.
Take exactly as prescribed; do not skip doses or change brands without consulting your doctor.,Do not stop taking suddenly as this may cause withdrawal seizures.,Avoid alcohol as it can affect drug levels and increase side effects.,Report any rash, fever, swollen glands, or mouth sores immediately (risk of Stevens-Johnson syndrome).,Use reliable contraception if sexually active; phenytoin reduces effectiveness of hormonal contraceptives.,Maintain good dental hygiene and see dentist regularly; may cause gum overgrowth.,Take with food if stomach upset occurs, but avoid high-fat meals if consistent timing is needed.,May cause dizziness, drowsiness, or blurred vision; avoid driving until you know how it affects you.
Use AZMIRO exactly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking this medication without talking to your doctor.,Tell your doctor if symptoms worsen or you need more rescue inhaler.,Avoid foods high in potassium if you are also taking diuretics.
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Phenytoin is a potent inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes. Dasatinib is primarily metabolized by CYP3A4. Coadministration with phenytoin significantly reduces dasatinib plasma concentrations, potentially leading to subtherapeutic levels, reduced efficacy, and increased risk of disease progression in chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia."
"Phenytoin, a known inducer of CYP450 enzymes (particularly CYP3A4 and CYP2C9), increases the hepatic metabolism of ambroxol, a mucolytic agent primarily metabolized via CYP3A4. This induction reduces ambroxol plasma concentrations, potentially diminishing its therapeutic efficacy in clearing respiratory secretions. Clinically, patients may experience reduced mucolytic effects, leading to inadequate clearance of bronchial secretions and worsening of underlying respiratory conditions."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENYTOIN vs AZMIRO, answered by our medical review team.
PHENYTOIN is a Anticonvulsant that works by Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.. AZMIRO is a Anticonvulsant that works by Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENYTOIN and AZMIRO depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENYTOIN is: Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.. The standard adult dose of AZMIRO is: Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENYTOIN and AZMIRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENYTOIN is classified as Category D/X. Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during f. AZMIRO is classified as Category C. No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.